Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Horowitz

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Optics Letters|December 1, 2005
Compensation for multimode fiber dispersion by adaptive opticsXiling Shen, Joseph M Kahn, Mark A Horowitz
Journal of Child and Adolescent Psychopharmacology|September 19, 2023
Re: "A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder" by Strawn et al.-Concerning Harm-Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety DisorderMartin Plöderl, Mark A Horowitz, Michael P Hengartner
Australian Journal of General Practice|June 4, 2026
Continuing antidepressants or not: Evaluating the potential benefits and harmsKatharine A Wallis, Joanna Moncrieff, Mark A Horowitz
Journal of Clinical Epidemiology|January 18, 2026
The loss of efficacy of fluoxetine in pediatric depression: explanations, lack of acknowledgment, and implications for other treatmentsMartin Plöderl, Richard Lyus, Mark A Horowitz, et al.
Therapeutic Advances in Psychopharmacology|September 16, 2024
Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugsJames R O'Neill, David M Taylor, Mark A Horowitz
Therapeutic Advances in Psychopharmacology|September 18, 2023
Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an <i>in silico</i> modelling studyJames R O'Neill, David M Taylor, Mark A Horowitz
Journal of Clinical Epidemiology|January 20, 2026
Reply to "Some additional considerations on the evidence for flouxetine in pediatric depression"Martin Plöderl, Richard Lyus, Mark A Horowitz, et al.
Psychological Medicine|October 10, 2025
False reassurances based on inadequate data not helpfulMark A Horowitz, Michael P Hengartner, Martin Plöderl, et al.
Journal of Affective Disorders|August 23, 2025
Alternate-day dosing to taper antidepressants risks severe withdrawal effects: an in silico analysisJames R O'Neill, Anders Sørensen, David Taylor, et al.
Developmental Neuroscience|June 11, 2023
Fluoxetine Can Cause Epileptogenesis and Aberrant Neurogenesis in Male Wild-Type MiceKsenia Musaelyan, Mark A Horowitz, Stephen McHugh, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Optics Letters|December 1, 2005
Compensation for multimode fiber dispersion by adaptive opticsXiling Shen, Joseph M Kahn, Mark A Horowitz
Journal of Child and Adolescent Psychopharmacology|September 19, 2023
Re: "A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder" by Strawn et al.-Concerning Harm-Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety DisorderMartin Plöderl, Mark A Horowitz, Michael P Hengartner
Australian Journal of General Practice|June 4, 2026
Continuing antidepressants or not: Evaluating the potential benefits and harmsKatharine A Wallis, Joanna Moncrieff, Mark A Horowitz
Journal of Clinical Epidemiology|January 18, 2026
The loss of efficacy of fluoxetine in pediatric depression: explanations, lack of acknowledgment, and implications for other treatmentsMartin Plöderl, Richard Lyus, Mark A Horowitz, et al.
Therapeutic Advances in Psychopharmacology|September 16, 2024
Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugsJames R O'Neill, David M Taylor, Mark A Horowitz
Therapeutic Advances in Psychopharmacology|September 18, 2023
Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an <i>in silico</i> modelling studyJames R O'Neill, David M Taylor, Mark A Horowitz
Journal of Clinical Epidemiology|January 20, 2026
Reply to "Some additional considerations on the evidence for flouxetine in pediatric depression"Martin Plöderl, Richard Lyus, Mark A Horowitz, et al.
Psychological Medicine|October 10, 2025
False reassurances based on inadequate data not helpfulMark A Horowitz, Michael P Hengartner, Martin Plöderl, et al.
Journal of Affective Disorders|August 23, 2025
Alternate-day dosing to taper antidepressants risks severe withdrawal effects: an in silico analysisJames R O'Neill, Anders Sørensen, David Taylor, et al.
Developmental Neuroscience|June 11, 2023
Fluoxetine Can Cause Epileptogenesis and Aberrant Neurogenesis in Male Wild-Type MiceKsenia Musaelyan, Mark A Horowitz, Stephen McHugh, et al.
Pageof 5